ArticleBMJ open2021

A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.

Stephen J Freedland et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.